Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GPhA’s New VP-Regulatory Sciences Has Expertise In Generic Injectable Business

This article was originally published in The Pink Sheet Daily

Executive Summary

During nine years at Ben Venue, Gaugh was responsible for strategic planning, financial management, business development, marketing and sales for the company’s $500 million branded generic injectable business, which is now struggling with manufacturing challenges.

Advertisement

Related Content

Drug Shortages Give Ben Venue Relief In FDA Consent Decree
Drug Shortages Give Ben Venue Relief In FDA Consent Decree
People In The News: Tracking The Latest Industry Personnel Moves
FDA Meetings With Biosimilar Sponsors Aim To Make 351(k) Pathway OK
FDA’s Drug Shortage Prevention Tally: 96 Saves In Six Weeks
Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections
GPhA's New CEO Ralph Neas Brings Health Reform Advocacy Experience

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073239

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel